Baudax Bio Stock (NASDAQ:BXRX)
Previous Close
$NaN
52W Range
$0.19 - $0.19
50D Avg
-
200D Avg
-
Market Cap
-
Avg Vol (3M)
$424.85K
Beta
1.58
Div Yield
-
BXRX Company Profile
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
BXRX Performance
Peer Comparison
Ticker | Company |
---|---|
BDRX | Biodexa Pharmaceuticals Plc |
CFRX | ContraFect Corporation |
CNSP | CNS Pharmaceuticals, Inc. |
ENSC | Ensysce Biosciences, Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
YS | LakeShore Biopharma Co., Ltd |
HILS | Tharimmune, Inc. |
DRMA | Dermata Therapeutics, Inc. |
VRAX | Virax Biolabs Group Limited |
ALLR | Allarity Therapeutics, Inc. |
CYTO | Altamira Therapeutics Ltd. |
NRBO | NeuroBo Pharmaceuticals, Inc. |
WINT | Windtree Therapeutics, Inc. |
PALI | Palisade Bio, Inc. |